On this page you will find links to key resources and tools to enable robust vaccine trial design during the COVID-19 outbreak, as well as the latest information regarding ongoing vaccine trials and potential COVID-19 vaccines. 

Are you considering conducting a vaccine trial? If so, then please let us know what you have planned and if you need any support. Are you looking for groups to collaborate with? Do you want to let others know that you would like to collaborate with another group?

We want to support any team wanting to run a high-quality COVID-19 trial in different settings, and especially in LMICs. We can help coordinate discussions and support your plans. We can also set up a forum for developing ideas and asking questions. Please get in touch and get involved!

UNICEF and PAHO launch joint COVID-19 vaccine tender on behalf of COVAX Facility

UNICEF and PAHO announced on the 12th of November the launch of a tender inviting all COVID-19 vaccine developers to submit a proposal for supply in 2021. The tender, which will run for 6 weeks, aims to provide at least 2 billion doses of COVID-19 vaccines on behalf of the COVAX Facility, administered by Gavi, the Vaccine Alliance. The aim of the tender is to ensure equitable and accelerated access to quality assured vaccines for the 186 participating economies as of today.

UNICEF to stockpile over half a billion syringes by year end, as part of efforts to prepare for eventual COVID-19 vaccinations

As soon as COVID-19 vaccines successfully emerge from trials and are licensed and recommended for use, the world will need as many syringes as doses of vaccine. To begin preparations, this year, UNICEF will stockpile 520 million syringes in its warehouses, part of a larger plan of 1 billion syringes by 2021, to guarantee initial supply and help ensure that syringes arrive in countries before the COVID-19 vaccines.

Science in 5 is WHO's Series in which WHO experts explain the science about specific issues related to COVID-19.

The transcript for the video can be found here.


What support is available?

The European Medicines Agency (EMA) encourages developers of potential vaccines or treatments for novel coronavirus infection to contact EMA as soon as possible to discuss their strategy for evidence-generation, by emailing 2019-ncov@ema.europa.eu. The EMA can also provide medicine developers with scientific advice on the most appropriate way to generate robust evidence on a medicine's benefits and risks. Scientific advice is free of charge and can be fast-tracked for potential novel coronavirus treatments or vaccines.

In response to the emergence of COVID-19, the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) has developed a portfolio of resources to accelerate outbreak research and response.

Fundação Oswaldo Cruz (Fiocruz) has created a resource area highlighting important sources of information about the pandemic, to facilitate the circulation of knowledge and help the entire scientific community to keep abreast of the latest news about the disease. 

Use the buttons below to navigate the areas of the COVID-19 Research Implementation Hub